Journal of Clinical Endocrinology & Metabolism, Vol 69, 1093-1096, Copyright © 1989 by Endocrine Society

ARTICLES

Clinical review 3: The clinical use of thyrotropin receptor antibody measurements

JM McKenzie and M Zakarija
Department of Medicine, University of Miami School of Medicine, Florida 33101.

There are relatively few circumstances wherein the assay of TRAb, as TSAb or TBIAb, is merited in the routine clinical management of patients with autoimmune thyroid disease. These include: 1. the prediction of neonatal hyperthyroidism; 2. the confirmation, by assay of maternal serum, and perhaps newborn blood, that neonatal hypothyroidism, identified on routine screening, may be transient and due to transplacental passage of TBIAb; 3. the prediction of relapse of hyperthyroidism at the end of a course of antithyroid drugs; this information should lead to more careful observation to identify relapse as early as possible; 4. the confirmation that adult agoitrous hypothyroidism reflects the effect of an antibody (TBIAb) blocking the action of TSH although, as discussed, there is little, if any, practical gain from this information. Additional applications of the routine use of TRAb assays will require the development of a procedure that combines the sensitivity, specificity, availability, and ease found variably in current TSAb and TBI procedures, and at much less cost than what is provided today.

This article has been cited by other articles:

				D. Peleg, S. Cada, A. Peleg, and M. Ben-Ami The Relationship Between Maternal Serum Thyroid-Stimulating Immunoglobulin and Fetal and Neonatal Thyrotoxicosis Obstet. Gynecol., June 1, 2002; 99(6): 1040 - 1043. [Abstract] [Full Text] [PDF]

				C. Massart and D. Maugendre Importance of the Detection Method for Thyroglobulin Antibodies for the Validity of Thyroglobulin Measurements in Sera from Patients with Graves Disease Clin. Chem., January 1, 2002; 48(1): 102 - 107. [Abstract] [Full Text] [PDF]

				S. Kaithamana, J. Fan, Y. Osuga, S.-G. Liang, and B. S. Prabhakar Induction of Experimental Autoimmune Graves' Disease in BALB/c Mice J. Immunol., November 1, 1999; 163(9): 5157 - 5164. [Abstract] [Full Text] [PDF]

				B. Rapoport, G. D. Chazenbalk, J. C. Jaume, and S. M. McLachlan The Thyrotropin (TSH)-Releasing Hormone Receptor: Interaction with TSH and Autoantibodies Endocr. Rev., December 1, 1998; 19(6): 673 - 716. [Abstract] [Full Text]

				E. Roti, L. E. Braverman, and L. J. DeGroot TSH Receptor Antibody Measurement in the Diagnosis and Management of Graves' Disease Is Rarely Necessaryb J. Clin. Endocrinol. Metab., November 1, 1998; 83(11): 3781 - 3784. [Full Text]

				R. Paschke and M. Ludgate The Thyrotropin Receptor in Thyroid Diseases N. Engl. J. Med., December 4, 1997; 337(23): 1675 - 1681. [Full Text] [PDF]

				A. Kakinuma, G. D. Chazenbalk, J. C. Jaume, B. Rapoport, and S. M. McLachlan The Human Thyrotropin (TSH) Receptor in a TSH Binding Inhibition Assay for TSH Receptor Autoantibodies J. Clin. Endocrinol. Metab., July 1, 1997; 82(7): 2129 - 2134. [Abstract] [Full Text] [PDF]

				S. A. Patibandla, J. S. Dallas, G. S. Seetharamaiah, K. Tahara, L. D. Kohn, and B. S. Prabhakar Flow Cytometric Analyses of Antibody Binding to Chinese Hamster Ovary Cells Expressing Human Thyrotropin Receptor J. Clin. Endocrinol. Metab., June 1, 1997; 82(6): 1885 - 1893. [Abstract] [Full Text] [PDF]

				M P J Vanderpump, J A O Ahlquist, J A Franklyn, and R N Clayton Consensus statement for good practice and audit measures in the management of hypothyroidism and hyperthyroidism BMJ, August 31, 1996; 313(7056): 539 - 544. [Full Text]